FR13C0013I2 - Analogues de peptide 2 du type glucagon - Google Patents

Analogues de peptide 2 du type glucagon

Info

Publication number: FR13C0013I2
Authority: FR; France
Prior art keywords: glucagon; analogs; type peptide; peptide; synthesis
Prior art date: 1996-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR13C0013C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

1506385 Alberta Ltd

Shire NPS Pharmaceuticals Inc

Original Assignee

1506385 Alberta Ltd

NPS Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-12

Filing date

2013-02-22

Publication date

2013-08-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-02-22 Application filed by 1506385 Alberta Ltd, NPS Pharmaceuticals Inc filed Critical 1506385 Alberta Ltd

2013-05-04 Publication of FR13C0013I1 publication Critical patent/FR13C0013I1/fr

2013-08-16 Application granted granted Critical

2013-08-16 Publication of FR13C0013I2 publication Critical patent/FR13C0013I2/fr

Status Active legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title 1
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000008467 tissue growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

FR13C0013C 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon Active FR13C0013I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63127396A	1996-04-12	1996-04-12
PCT/CA1997/000252 WO1997039031A1 (fr)	1996-04-12	1997-04-11	Analogues de peptide 2 du type glucagon

Publications (2)

Publication Number	Publication Date
FR13C0013I1 FR13C0013I1 (fr)	2013-05-04
FR13C0013I2 true FR13C0013I2 (fr)	2013-08-16

Family

ID=24530501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR13C0013C Active FR13C0013I2 (fr)	1996-04-12	2013-02-22	Analogues de peptide 2 du type glucagon

Country Status (16)

Country	Link
EP (5)	EP2009024A1 (fr)
JP (3)	JP4148994B2 (fr)
CN (1)	CN1268640C (fr)
AT (2)	ATE227309T1 (fr)
AU (1)	AU733857B2 (fr)
BR (1)	BRPI9708566B8 (fr)
CA (1)	CA2251576C (fr)
DE (2)	DE69716905T2 (fr)
DK (2)	DK0906338T3 (fr)
ES (2)	ES2351661T3 (fr)
FR (1)	FR13C0013I2 (fr)
HK (1)	HK1050204B (fr)
LU (1)	LU92153I2 (fr)
NZ (1)	NZ332281A (fr)
PT (2)	PT906338E (fr)
WO (1)	WO1997039031A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
ES2351661T3 (es) *	1996-04-12	2011-02-09	1149336 Ontario Inc.	Péptido-2 análogo al glucagón.
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
CA2236519C (fr)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methodes pour ameliorer le fonctionnement du gros intestin
BR9808804A (pt) *	1997-05-16	2001-09-18	Ontario Inc	Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas
EP1060192A2 (fr) *	1998-02-27	2000-12-20	Novo Nordisk A/S	Derives de glp-2 avec teneur en structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
WO1999058144A1 (fr) *	1998-05-11	1999-11-18	1149336 Ontario Inc.	Procedes d'amelioration du fonctionnement du gros intestin
GB9930882D0 (en)	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
EP1326630B1 (fr)	2000-09-18	2008-05-28	Sanos Bioscience A/S	Utilisation de peptides glp-2
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (fr) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Composes glp-2, leurs formulations et leurs utilisations
EP1592471B1 (fr) *	2003-02-04	2011-03-23	Novo Nordisk A/S	Dispositif d'injection comportant un mecanisme de dosage rotatif
JP2007526235A (ja) *	2003-08-21	2007-09-13	ノボ　ノルディスク　アクティーゼルスカブ	グルカゴン様ペプチドの精製
RU2385879C2 (ru)	2004-01-21	2010-04-10	Ново Нордиск Хелс Кеа Аг	Способ конъюгации пептидов, опосредованной трансглутаминазой
ES2427150T3 (es)	2004-11-01	2013-10-29	Nps Pharmaceuticals, Inc.	Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
EP2295451A1 (fr)	2005-05-04	2011-03-16	Zealand Pharma A/S	Analogues du glucagon-like peptide-2 (GLP-2)
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
CN101573376B (zh) *	2006-11-08	2013-11-06	西兰制药公司	选择性胰高血糖素样肽-2（glp-2）类似物
CN101824087A (zh) *	2009-03-05	2010-09-08	连云港恒邦医药科技有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (fr) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 en utilisation pour la récupération intestinale et musculaire
EP2314616A1 (fr) *	2009-10-23	2011-04-27	Ferring B.V.	Agonistes peptidiques de GLP-2
EP2495255A4 (fr) *	2009-10-30	2013-05-15	Otsuka Chemical Co Ltd	Forme glycosylée d'analogue du glp-1 antigénique
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
JP2013526535A (ja) *	2010-05-11	2013-06-24	エヌピーエスファーマシューティカルズインコーポレイテッド	腎機能障害または肝機能障害の治療または予防のための方法
EP2694083A2 (fr)	2011-04-01	2014-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Peptides et compositions pharmaceutiques utilisés dans un traitement par voie nasale, destiné à des patients atteints d'anxiété et de troubles du sommeil
CN102924589B (zh) *	2011-08-11	2016-08-24	中肽生化有限公司	胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
CA2872315A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Analogues du glucagon-like peptide 2 (glp-2)
CN103159848B (zh) *	2013-01-06	2015-11-25	中国人民解放军第四军医大学	人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
EP3526242A1 (fr)	2016-10-12	2019-08-21	University of Copenhagen	Agonistes doubles peptidiques de gipr et glp2r
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
TWI791539B (zh)	2017-06-16	2023-02-11	丹麥商西蘭製藥公司	用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
WO2019086559A1 (fr)	2017-10-31	2019-05-09	Adocia	Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (fr)	2018-07-23	2020-01-30	Zealand Pharma A/S	Utilisations thérapeutiques d'agonistes de glp-2
EP3628682A1 (fr)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations d'analogues glucagon-like-peptide-2 (glp-2)
EP3628683A1 (fr)	2018-09-28	2020-04-01	Zealand Pharma A/S	Formulations d'analogues de peptide-2 de type glucagon (glp-2)
KR20210126088A (ko)	2019-02-11	2021-10-19	옵코 바이오로직스 리미티드	지속성 glp-2 유사체
KR20220150270A (ko)	2019-10-07	2022-11-10	칼리오페, 인크.	Gpr119 효능제
JP7745559B2 (ja)	2020-02-28	2025-09-29	キャリーオペ，インク．	Ｇｐｒ４０アゴニスト
US20230110689A1 (en)	2020-03-30	2023-04-13	Zealand Pharma A/S	Agonist combination
CA3240750A1 (fr) *	2021-12-17	2023-06-22	Bainan Biotech Aps	Agonistes doubles peptidiques de gipr et glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en)	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1575343A (en)	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4529561A (en)	1978-03-24	1985-07-16	The Regents Of The University Of California	Method for producing liposomes in selected size range
GB2046092B (en)	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en)	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4725442A (en)	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en)	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5009956A (en)	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
US4927637A (en)	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
JP2961045B2 (ja) *	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
CA2137206A1 (fr)	1993-12-09	1995-06-10	John A. Galloway	Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
DK0891378T3 (da)	1996-03-01	2003-01-06	Novo Nordisk As	Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid
ES2351661T3 (es) *	1996-04-12	2011-02-09	1149336 Ontario Inc.	Péptido-2 análogo al glucagón.
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (fr)	2001-02-01	2002-08-29	Drucker Daniel J	Renforcement de l'activite de glp-2

1997
- 1997-04-11 ES ES01129072T patent/ES2351661T3/es not_active Expired - Lifetime
- 1997-04-11 AT AT97916280T patent/ATE227309T1/de active
- 1997-04-11 EP EP08154386A patent/EP2009024A1/fr not_active Withdrawn
- 1997-04-11 JP JP53660897A patent/JP4148994B2/ja not_active Expired - Lifetime
- 1997-04-11 AU AU25002/97A patent/AU733857B2/en not_active Expired
- 1997-04-11 AT AT01129072T patent/ATE478892T1/de active
- 1997-04-11 PT PT97916280T patent/PT906338E/pt unknown
- 1997-04-11 EP EP10012937A patent/EP2275438A1/fr not_active Withdrawn
- 1997-04-11 WO PCT/CA1997/000252 patent/WO1997039031A1/fr not_active Ceased
- 1997-04-11 NZ NZ332281A patent/NZ332281A/xx not_active IP Right Cessation
- 1997-04-11 DE DE69716905T patent/DE69716905T2/de not_active Expired - Lifetime
- 1997-04-11 ES ES97916280T patent/ES2188929T3/es not_active Expired - Lifetime
- 1997-04-11 DE DE60142885T patent/DE60142885D1/de not_active Expired - Lifetime
- 1997-04-11 DK DK97916280T patent/DK0906338T3/da active
- 1997-04-11 EP EP97916280A patent/EP0906338B1/fr not_active Expired - Lifetime
- 1997-04-11 EP EP01129072A patent/EP1231219B1/fr not_active Expired - Lifetime
- 1997-04-11 BR BRPI9708566A patent/BRPI9708566B8/pt active IP Right Grant
- 1997-04-11 DK DK01129072.3T patent/DK1231219T3/da active
- 1997-04-11 EP EP10163303.0A patent/EP2218734B1/fr not_active Expired - Lifetime
- 1997-04-11 CN CNB971953317A patent/CN1268640C/zh not_active Expired - Lifetime
- 1997-04-11 CA CA2251576A patent/CA2251576C/fr not_active Expired - Lifetime
2001
- 2001-12-07 PT PT01129072T patent/PT1231219E/pt unknown
2003
- 2003-02-07 HK HK03100905.1A patent/HK1050204B/en not_active IP Right Cessation
2007
- 2007-04-24 JP JP2007114302A patent/JP4149497B2/ja not_active Expired - Lifetime
2008
- 2008-02-07 JP JP2008027918A patent/JP5019466B2/ja not_active Expired - Lifetime
2013
- 2013-02-19 LU LU92153C patent/LU92153I2/fr unknown
- 2013-02-22 FR FR13C0013C patent/FR13C0013I2/fr active Active

Also Published As

Publication number	Publication date
BRPI9708566A (pt)	2000-01-04
AU733857B2 (en)	2001-05-31
WO1997039031A1 (fr)	1997-10-23
HK1033324A1 (en)	2001-08-24
ES2188929T3 (es)	2003-07-01
DE69716905T2 (de)	2003-07-24
EP2009024A1 (fr)	2008-12-31
BR9708566B1 (pt)	2012-09-04
FR13C0013I1 (fr)	2013-05-04
EP1231219B1 (fr)	2010-08-25
EP0906338A1 (fr)	1999-04-07
EP2218734A3 (fr)	2010-10-13
EP1231219A1 (fr)	2002-08-14
EP2218734A2 (fr)	2010-08-18
JP2008184465A (ja)	2008-08-14
CN1244872A (zh)	2000-02-16
DE60142885D1 (de)	2010-10-07
EP2218734B1 (fr)	2013-06-05
CA2251576A1 (fr)	1997-10-23
DE69716905D1 (de)	2002-12-12
ATE478892T1 (de)	2010-09-15
EP0906338B1 (fr)	2002-11-06
CA2251576C (fr)	2012-08-21
ATE227309T1 (de)	2002-11-15
JP4148994B2 (ja)	2008-09-10
JP2000511881A (ja)	2000-09-12
HK1147761A1 (en)	2011-08-19
DK1231219T3 (da)	2010-12-20
NZ332281A (en)	2000-03-27
CN1268640C (zh)	2006-08-09
ES2351661T3 (es)	2011-02-09
PT906338E (pt)	2003-03-31
JP5019466B2 (ja)	2012-09-05
HK1050204B (en)	2011-09-23
JP4149497B2 (ja)	2008-09-10
EP2275438A1 (fr)	2011-01-19
LU92153I2 (fr)	2013-04-19
JP2007204491A (ja)	2007-08-16
HK1050204A1 (en)	2003-06-13
AU2500297A (en)	1997-11-07
DK0906338T3 (da)	2003-03-03
PT1231219E (pt)	2010-11-30
BRPI9708566B8 (pt)	2022-01-18

Publication	Publication Date	Title
FR13C0013I2 (fr)	2013-08-16	Analogues de peptide 2 du type glucagon
HUP0100928A2 (hu)	2001-08-28	Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUT64298A (en)	1993-12-28	Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
IL112585A (en)	2000-08-31	N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them
HUT64235A (en)	1993-12-28	Process for the production of medical prepartives containing by means of peroral introduction of insuline
ATE245435T1 (de)	2003-08-15	Totalsynthese des amino hip analogen von didemnin a
CY1107391T1 (el)	2010-07-28	Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
EP1184388A4 (fr)	2002-10-16	Analogues de la sulphostine et procede de preparation de la sulphostine et de ses analogues
DK0833646T3 (da)	2000-05-08	Multi-tyrosinerede somatostatinanaloger
SE9903291D0 (sv)	1999-09-15	New process
HUT60712A (en)	1992-10-28	Process for producing aspartame from diketopiperazine and process for producing intermediates
ATE236139T1 (de)	2003-04-15	Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
ES2196088T3 (es)	2003-12-16	Analogos del factor de crecimiento de los queratinocitos.
IL112098A0 (en)	1995-03-15	Sulfamate derivatives and pharmaceutical compositions containing them
GR920100570A (el)	1993-08-31	Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
ZA896245B (en)	1990-04-25	A new antibiotic,mersacidin,a process for the preparation thereof and the use thereof as a pharmaceutical
ES2144698T3 (es)	2000-06-16	Procedimiento para preparar un derivado de biciclohexano.
NO175745C (no)	1994-11-30	Analogifremgangsmåte for fremstilling av dibenzo(1,5)-dioksocin-5-oner
DE59610819D1 (de)	2003-12-18	Arzneistoffe zur selektiven bekämpfung von tumorgewebe
ATE121726T1 (de)	1995-05-15	Hydroquinonester von aminosäuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische oder kosmetische zusammensetzungen.
EP0603399A4 (en)	1997-03-05	Endothelin-antagonizing peptide.
SE9800865D0 (sv)	1998-03-16	New Process
SE9203824L (sv)	1993-06-28	Bensofuranylimidazol-derivat, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma
FR2563727B3 (fr)	1987-05-07	Nouveau procede de preparation de greffon de peau a partir d'un tissu conjonctif natif
HU910463D0 (en)	1991-08-28	Process for the production of medical preparation